German-based Grünenthal Group has signed an agreement with Astellas Pharma Europe for the exclusive rights to the dermal patch Qutenza (capsaicin 8%) in Europe, the Middle East and Africa.

The European Medicines Agency (EMA) approved Qutenza in 2009 for the treatment of peripheral neuropathic pain (PNP) excluding diabetic polyneuropathy (DPN).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

After obtaining a label extension last year, DPN is now included and has broadened the Qutenza label to all peripheral neuropathic pain subgroups.

Grünenthal Group CEO Gabriel Baertschi said: “We have a clear strategy to further build our pain portfolio through in-house innovation and external acquisition.

“Adding Qutenza is a perfect strategic fit and will broaden the options available to physicians, especially in localised neuropathic pain; an area of remaining high unmet need for patients."

See Also:

"Grünenthal has a long track record in pain and will be well placed to provide Qutenza to more patients who stand to benefit."

Under the agreement, Grünenthal will hold rights for Qutenza in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, as well as other East European, Middle East and African countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Astellas Pharma Europe operations president Yukio Matsui said: “This agreement is a part of our work toward higher quality and efficiency of operations through optimisation of resources and will ultimately provide hope for more patients around the world.

“Grünenthal has a long track record in pain and will be well placed to provide Qutenza to more patients who stand to benefit.”

NeurogesX developed the high-dose capsaicin (8%) containing Qutenza and licensed it to Astellas Pharma Europe in 2009.

The capsaicin 8% patch is currently approved for use in 27 countries across Europe and is applied to the area of pain to reduce the neuropathic pain intensity.